Literature DB >> 9096581

Hepatic venous outflow block caused by short-length hepatic vein stenoses.

D Valla1, A Hadengue, M el Younsi, N Azar, G Zeitoun, M J Boudet, G Molas, J Belghiti, S Erlinger, J M Hay, J P Benhamou.   

Abstract

In contrast with the well-recognized membranous obstruction of the inferior vena cava, short-length hepatic vein stenoses are not well-recognized causes of hepatic venous outflow block. The aim of this study was to ascertain the prevalence, causes, manifestations, and outcome of short-length hepatic vein stenoses. We performed a retrospective study of patients with short-length hepatic vein stenosis among 86 patients with hepatic venous outflow block who were seen between 1970 and 1992. There were 25 patients with short-length hepatic vein stenosis. A thrombogenic condition was identified in 14 patients (56%). The lesions of the accompanying hepatic veins in these patients were variable (short-length stenoses, thromboses, or nonspecific changes) and similar to that seen in patients without short-length hepatic vein stenosis. In 3 necropsied cases, the venous lesions were suggestive of fibrous sequela of prior thromboses. In patients with short-length hepatic vein stenosis, splenomegaly (28% vs. 55%, P < .05) and hypersplenism were significantly less common; serum transaminase (P < .001) and creatinine levels (P < .02) were lower, prothrombin was higher (P < .001), and 5-year survival was significantly better (Kaplan-Meier estimates: 80% vs. 50%, P < .05). In patients with hepatic venous outflow block, short-length hepatic vein stenosis is a common lesion that appears to be the sequela of localized thrombosis. Long-term anticoagulation and percutaneous angioplasty (with or without stenting) are potentially applicable in these lesions. The long-term results of these treatments merit further evaluation.

Entities:  

Mesh:

Year:  1997        PMID: 9096581     DOI: 10.1002/hep.510250405

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

1.  Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome.

Authors:  C E Eapen; D Velissaris; M Heydtmann; B Gunson; S Olliff; E Elias
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

2.  Prognosis in Budd Chiari syndrome after re-establishing hepatic venous drainage.

Authors:  D-C Valla
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

3.  Factor V Leiden related Budd-Chiari syndrome.

Authors:  P Deltenre; M H Denninger; S Hillaire; M C Guillin; N Casadevall; J Brière; S Erlinger; D C Valla
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 4.  Budd-Chiari syndrome/hepatic venous outflow tract obstruction.

Authors:  Dominique-Charles Valla
Journal:  Hepatol Int       Date:  2017-07-06       Impact factor: 6.047

5.  Managing Budd-Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting.

Authors:  N C Fisher; I McCafferty; M Dolapci; M Wali; J A Buckels; S P Olliff; E Elias
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

Review 6.  Budd-Chiari syndrome and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2015-02

7.  Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome.

Authors:  Chun-Qing Zhang; Li-Na Fu; Lin Xu; Guo-Quan Zhang; Tao Jia; Ji-Yong Liu; Cheng-Yong Qin; Ju-Ren Zhu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 8.  Budd-Chiari syndrome.

Authors:  Pieter Martens; Frederik Nevens
Journal:  United European Gastroenterol J       Date:  2015-12       Impact factor: 4.623

9.  Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival.

Authors:  Yan-Feng Cui; Yu-Fei Fu; De-Chun Li; Hao Xu
Journal:  Hepatol Int       Date:  2015-10-23       Impact factor: 6.047

Review 10.  An Update on the Management of Budd-Chiari Syndrome.

Authors:  A Sharma; S N Keshava; A Eapen; E Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2020-07-20       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.